Table 5.

Time Course to Muscle-Related Adverse-Effect Onset and Recovery for Trials of Statins That Resulted in Muscle-Related Adverse Effects

Time Course for Trials of Statins	No. of Patients Responding	Time to Onset or Recovery (wks)
		Median	Mean ± SD	Rangea
First trials resulting in MAEsb
Time to MAE onset after starting the statin	301	14	55 ± 95	0.14–520
Time to first noted recovery after statin discontinuation	189	2	8 ± 16	0.14–144
Time to maximal recovery after statin discontinuation	149	8	29 ± 64	0.14–624
Time to complete recovery after statin discontinuation (confined to those reporting complete recovery)	70	4	14 ± 19	0.14–96
Index vs rechallenge trial resulting in MAEsb
Time to onset, first occurrence, in those with rechallenge datac	98	12	43 ± 78	0.14–520
Time to onset after first rechallengec	98	2	15 ± 42	0.14–286
Time to recovery, first occurrence, in those with rechallenge datad	56	2	6 ± 11	0.14–48
Time to recovery after first rechallenged	56	2	12 ± 39	0.14–286
Rechallenge trials resulting in MAEs
Time to first noted recovery after first statin rechallenge discontinued	72	2	8 ± 18	0.14–104
Time to maximal recovery after first statin rechallenge discontinued	62	10	27 ± 43	0.14–208
Time to complete recovery after first statin rechallenge discontinued (confined to those reporting complete recovery)	33	4	9 ± 14	0.14–78

MAEs = muscle-related adverse effects.

^a0.14 wk = 1 day.

^bLimited to patients with time course data for both index and rechallenge MAEs.

^cPaired t test for index MAE onset vs first rechallenge onset, p=0.0014.

^dPaired t test for index MAE recovery vs first rechallenge recovery, p=0.24.